Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 1/20 | 0.64 |
| ▸ | EPHX1 | P07099 | 11/20 | 0.48 |
| ▸ | CASP2 | P42575 | 1/20 | 0.44 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.41 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.41 |
| ▸ | NAAA | Q02083 | 1/20 | 0.41 |
| ▸ | FAAH | O00519 | 1/20 | 0.38 |
| ▸ | S1PR2 | O95136 | 2/20 | 0.37 |
| ▸ | S1PR4 | O95977 | 2/20 | 0.37 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.37 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12344215 | 0.91 | KDM1A (0.69) | KDM1AEPHX1 | |
| SCHEMBL16573360 | 0.82 | — | — | |
| SCHEMBL14219765 | 0.82 | — | — | |
| SCHEMBL8257403 | 0.79 | KDM1A (0.44) | KDM1AEPHX1CASP2ZDHHC20ZDHHC2 | |
| SCHEMBL10045220 | 0.78 | KDM1A (1.00) | KDM1A | |
| SCHEMBL3507348 | 0.78 | KDM1A (1.00) | KDM1A | |
| SCHEMBL15787328 | 0.78 | KDM1A (0.81) | KDM1A | |
| SCHEMBL11484382 | 0.77 | EPHX1 (0.42) | KDM1AEPHX1CASP2ZDHHC20ZDHHC2 | |
| SCHEMBL11484378 | 0.77 | HRH4 (0.51) | KDM1AEPHX1CASP2ZDHHC20ZDHHC2 | |
| SCHEMBL13631010 | 0.77 | EPHX1 (0.42) | KDM1AEPHX1CASP2ZDHHC20ZDHHC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10308683-B2 | Bicyclic lipolantipeptide, preparation and use as antimicrobial agent | DEINOVE (FR) | 2019-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10308683-B2 | Bicyclic lipolantipeptide, preparation and use as antimicrobial agent | LCT, LIPE, VIP | KDM1A 4661/4885EPHX1 4417/4885CASP2 894/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.